Fixed Low-dose Eltrombopag and rhTPO for Immune Thrombocytopenia (FLOWER)
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This is a prospective, single-arm study to investigate the efficacy and safety of the
combination of fixed low-dose eltrombopag plus recombinant human thrombopoietin (rhTPO) as
treatment for corticosteroid-resistant or relapsed immune thrombocytopenia (ITP) patients
during the COVID-19 pandemic.